have indicated that ROS activation correlates with increased blood vessel proliferation, suppression of immune microenvironmental functions, and intensified production of macrophage IFN and IL-6, ultimately hampering the immune response in the tumor microenvironment (56–58). The gene discussed is IFNA1; the disease is neoplasm.